Comparison of Efficacy of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate on Chronic Hepatitis B

Yingyuan ZHANG; Chunyan MOU; Huan MU; Danqing XU; Lixian CHANG; Yuanzhen WANG; Chunyun LIU; Li LIU

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 >

Yingyuan ZHANG, Chunyan MOU, Huan MU, Danqing XU, Lixian CHANG, Yuanzhen WANG, Chunyun LIU, Li LIU. Comparison of Efficacy of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate on Chronic Hepatitis B[J]. Journal of Kunming Medical University.

Citation:

PDF( 688 KB)

Comparison of Efficacy of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate on Chronic Hepatitis B

1.
Department of Hepatology and Immunology，Kunming Third People’s Hospital/Yunnan Provincial Clinical Medical Center for Infectious Diseases，Kunming Yunnan 650041
2.
School of Public Health，Dali University，Dali Yunnan 671000，China

Received Date: 2024-07-31

Abstract

Abstract

Objective To compare the efficacy of Tenofovir Alafenamide （TMF） and Tenofovir Disoproxil Fumarate （TDF） in terms of liver function restoration, virus clearance, immune regulation, anti liver fibrosis, lipid metabolism, bone and renal safety, and adverse reactions. Methods A retrospective analysis was conducted on 110 patients with chronic hepatitis B （CHB） admitted to Kunming Third People's Hospital from January 2022 to December 2022. Patients were divided into the TMF treatment group （n = 55） and the TDF treatment group （n = 55） based on their treatment regimen. We compared the levels of transaminase levels, antiviral efficacy, T cell subsets, renal function electrolytes, lipid metabolism, four liver fibrosis-related indicators, and changes in liver stiffness grading before and after treatment in two groups of patients. The incidence of adverse reactions post-treatment was also compared. Results After 48 weeks of treatment, the levels of TBIL, ALT, AST, GGT, and GLOB in both groups of patientswere significantly lower than pre-treatment levels （P < 0.05）. The decrease in AST levels in the TMF group was lower than that in the TDF group （P < 0.05）. After 48 weeks of treatment, the HBV-DNA seroconversion rate in the TMF group （90.90%） was higher than that in the TDF group （83.64%）. The serological HBsAg seroconversion rate in the TMF group （7.3%） was lower than that in the TDF group （9.1%）, while the HBeAg seroconversion rate in the TMF group （38.2%） was significantly higher than that in the TDF group （18.2%）, with statistical significance （P < 0.05）. After 48 weeks of treatment, levels of CD3⁺, CD4⁺, and CD8⁺in both groups were significantly elevated compared to pre-treatment levels（P < 0.05）; notably, the TMF group had higher post-treatment levels of CD3⁺, CD4⁺, and CD8⁺ than the TDF group. After 48 weeks, the average values of HA, IV-C, and LN among the TMF group for liver fibrosis indicators were significantly lower than those in the TDF group（P < 0.05）. The proportions of F0 and F2 in both groups significantly increased post-treatment, while the proportions of F3 and F4 significantly decreased （P to be supplemented）; furthermore, the proportions of F0 and F2 in the TMF group were significantly higher than those in the TDF group, and the proportions of F3 and F4 in the TMF group were significantly lower than those in the TDF group （P < 0.05）. After 48 weeks, HDL-C levels in the TMF group increased compared to pre-treatment （P < 0.05）. There were no significant differences in TG, TC, HDL-C, or LDL-C levels in the TDF group compared to pre-treatment （P > 0.05）. After 48 weeks of treatment, there was no difference in the levels of BUN、Cr、P⁺, and Ca⁺in the TMF group compared to pre-treatment （P > 0.05）; however, BUN and Cr levels in the TDF group were significantly higher than pre-treatment levels, while P+ and Ca+ levels were significantly lower （P < 0.05）. The incidence of elevated uric acid and bone pain was significantly higher in the TMF group compared to the TDF group; the incidence of diarrhea and abdominal pain was slightly higher in the TMF group compared to the TDF group. Conclusion Compared to TDF, TMF demonstrates a higher rate of liver function recovery, a greater virological response, enhanced anti fibrotic efficacy, and improved drug safety, making it worthy of clinical application in the future.
- TMF,
- TDF,
- Clinical efficacy,
- Virus response rate,
- Drug safety

FullText(HTML)

References(20)

References

[1]	尤红,王福生,李太生,等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志,2023,26(3):457-478.
[2]	Cheng H,Liu S,Luo S,et al. Uptake of hepatitis B antiviral treatment: A panel data analysis of 31 provinces in China (2013-2020)[J]. Liver Int,2022,42(8):1762-1769. doi: 10.1111/liv.15321
[3]	Zhao C,Wang Liu Y,et al. Uncovering the mechanism of Tenofovir amibufenamide fumarate punch sticking by combining direct compression experiment and computational simulation[J]. Int J Pharm,2024,4(653):123813.
[4]	中国肝炎防治基金会,中华医学会感染病学分会,中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J]. 中华肝脏病杂志,2019,27(3):182-191.
[5]	Zhuang H,Weng X. Long-term treatment of chronic hepatitis B[J]. Zhong Hua Gan Zang Bing Za Zhi,2014,22(12):884-890.
[6]	Liang,X,Xie,Q,Shang,J,et al. Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?[J]. Gastroen Hepatol,2022,37(3):471-479. doi: 10.1111/jgh.15757
[7]	程能能. 我国首个原研口服抗HBV药物TMF结构优势解读——神奇的甲基化[J]. 肝脏,2021,26(12):1303-1305. doi: 10.3969/j.issn.1008-1704.2021.12.002
[8]	Nam J Y,Chang Y,Cho H,et al. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B[J]. Viral Hepat,2018,25(5):552-560. doi: 10.1111/jvh.12838
[9]	Liu L P,Wu X P,Cai T P,et al. Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia[J]. Zhong Hua Gan Zang Bing Za Zhi,2023,31(2):118-125.
[10]	雷婷,严俊,袁建涛. 血清GGT、GGT/ALT、甲胎蛋白、异常凝血酶原时间水平在早期原发性肝癌患者中的变化及意义[J]. 中国卫生工程学,2024,23(3):354-356.
[11]	Baudi I,Kawashima K,Isogawa M. HBV-specific CD8+ T-cell tolerance in the liver[J]. Front Immunol,2021,12:721-975.
[12]	Mooney A H,Draper S L,Burn O K,et al. Preclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells[J]. HEP Rep,2024,6(5):101038.
[13]	Ma H Y,Dong L,Quan S Z,et al. Comparison of four markers of hepatic fibrosis and hepatic function indices in patients with liver cirrhosis and hepatoma[J]. Ann Palliat Med,2021,10(4):4108-4121. doi: 10.21037/apm-20-1623
[14]	Fan K,Zan X Zhi Y,et al. Immune response gene 1 deficiency impairs Nrf2 activation and aggravates liver fibrosis in mice[J]. Biochem Bioph Res Co,2022,607 103-109.
[15]	Huang K,Li Q,Zeng W,et al. Ultrasound score combined with liver stiffness measurement by sound touch elastography for staging liver fibrosis in patients with chronic hepatitis B: A clinical prospective study[J]. Ann Transl Med,2022,10(6):271. doi: 10.21037/atm-22-505
[16]	Li L,Zhou J,Li Y,et al. Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study[J]. Front Pharmacol,2023,6(14):1165990.
[17]	Peng WT,Jiang C,Yang FL,et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study[J]. World Gastroentero,2023,29(44):5907-5918. doi: 10.3748/wjg.v29.i44.5907
[18]	Srisopa S,Kornjirakasemsan A,Treebupachatsakul P,et al. Incidence and risk factors of tenofovir disoproxil fumarate induced nephrotoxicity and renal function recovery,a hospital case-control study[J]. Infect Chemother,2023,55(2):226-236. doi: 10.3947/ic.2023.0001
[19]	Hong X,Cai Z Zhou,F,et al. Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models[J]. Front Pharmacol,2022,29(13):932934.
[20]	Liu Z,Jin Q,Zhang Y,et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B[J]. Aliment Pharm Therap,2021,54(9):1134-1149. doi: 10.1111/apt.16611

Relative Articles(20)

Relative Articles

[1]	Rui YIN, Guowei MA, Wenxi YUE, Haixia GU, Ying ZHOU, Jie CHEN. Efficacy of Nucleotide Analog Monotherapy and Combination Therapy with Interferon in Treating Chronic Hepatitis B. Journal of Kunming Medical University,
[2]	Shengxi YANG, Jiade ZHU, Qiurui LI, Wenlian TU. Clinical Study of Aumolertinib Versus Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Journal of Kunming Medical University,
[3]	Hongbo ZHANG, Zhenlong LI, Ying LV, Yichao ZHANG, Xiangming QIU, Tingting HUANG. Comparison of Clinical Efficacy of Single-port and Double-port Video-assisted Thoracoscopic Lobectomy in the Treatment of Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240419
[4]	Zhongqiang ZHANG, Lili HU, Junli CHEN. Clinical Efficacy of Intrapleural Injection of Thrombin Combined with Drainage tube Suspension in the Treatment of Refractory Pneumothorax. Journal of Kunming Medical University,
[5]	Ling ZHAO, Hongling ZHONG, Xinru GAO, Mei LI, Tingting MAO, Rongyong LI, Tingyu KE. Clinical Observation of SGLT-2 Inhibitors in Delaying the Progression of Diabetic Nephropathy. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230527
[6]	Xiaolin LIU, Xiaocui CHEN, Yang SUN, Minli LI, Yinglei MIAO. Clinical Efficacy and Safety Evaluation of Fecal Bacteria Transplantation by Different Ways on Ulcerative Colitis. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20220612
[7]	Yanfei WANG, Juan MA, Yunqiao YANG. Clinical Efficacy and Safety of Sacubatril Valsartan in Patients with Reduced Ejection Fraction Combined with Hypotensive Heart Failure. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20221117
[8]	Li LIU, Jun-yi LI, Chun-yun LIU, Ying-rong DU, Jian-peng GAO, Hui-ming LI, Wei-kun LI, Yan-wei QI, Hui WANG. Effect of Tenofovir Combined with Ganshuang Granule on Hemodynamics of Portal Vein System in Hepatitis B Liver Cirrhosis. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20211125
[9]	Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210141
[10]	Jian-ming SUN, Qin SU, Kun-xiang WANG, Chun-yan ZHAO, Yuan LI, Quan-hong LI, Ming PU. Clinical Study of HIMSS Stage 6 Technology in Preventing Medication Errors in Children. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210427
[11]	Pu Dong , Li Xiao Fei , Yu Ting Ting , Wang Hong Ying , Zhang Run Wu , Li Li Hua , Bai Jing , Ding Cai Mei , Li Dong Ling , Yang Yong Rui . . Journal of Kunming Medical University,
[12]	Li Zhong Xi , Bai Jing Song , Tian Bo , Zhou Wen Jing , Liu Jun . . Journal of Kunming Medical University,
[13]	Wang Juan . Influence of Comprehensive Nursing Intervention on Clinical Efficacy and Complications of Patients with Nephrotic Syndrome. Journal of Kunming Medical University,
[14]	Zhang Qiong Yu . . Journal of Kunming Medical University,
[15]	Zhang Li Juan . . Journal of Kunming Medical University,
[16]	Gu Yong Fang . . Journal of Kunming Medical University,
[17]	Kang Ying Hong . . Journal of Kunming Medical University,
[18]	Song Hua . . Journal of Kunming Medical University,
[19]	Tao Zhi Xing . Comparison of Clinical Efficacy between Holmium Laser and Pneumatic Ballistic Lithotripsy in Treatment of Kidney Stones. Journal of Kunming Medical University,
[20]	Jie Yan Hua . Chest X-ray Radiographic and CT Findings in Severe A (H1N1)Virus Infection. Journal of Kunming Medical University,